"Rounding out the contenders is CytoDyn (OTCMKTS
Post# of 148188
(Total Views: 541)
Posted On: 12/31/2021 6:00:40 AM
"Rounding out the contenders is CytoDyn (OTCMKTS: CYDY) with its positive phase 3 trial design for critical patients that just got the FDA’s attention and might have a chance to take death off the table"
https://www.benzinga.com/general/biotech/21/1...s-dominant
(5)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼